1. Home
  2. MRUS
  3. MRUS News

Latest Merus N.V. (MRUS) News on May 10, 2025

Merus First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
MRUS

Simply Wall St.

7 hours ago

Merus First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Merus N.V. (MRUS): Among the Best Cancer Stocks to Invest in for Long-Term Gain
MRUS

Insider Monkey

a day ago

Merus N.V. (MRUS): Among the Best Cancer Stocks to Invest in for Long-Term Gain

Merus to Present at BofA Securities 2025 Health Care Conference
MRUS

GlobeNewswire

2 days ago

Merus to Present at BofA Securities 2025 Health Care Conference

Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates
MRUS

Zacks

3 days ago

Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates

Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update
MRUS

GlobeNewswire

3 days ago

Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update

Earnings Preview: Merus N.V. (MRUS) Q1 Earnings Expected to Decline
MRUS

Zacks

3 days ago

Earnings Preview: Merus N.V. (MRUS) Q1 Earnings Expected to Decline

Merus Will Have a Best-in-Class Treatment for Head and Neck Cancer, Analysts Say
MRUS

Barrons.com

15 days ago

Merus Will Have a Best-in-Class Treatment for Head and Neck Cancer, Analysts Say

Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting
MRUS

GlobeNewswire

17 days ago

Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting

Is Merus (NASDAQ:MRUS) the Best High Short Interest Stock to Buy Now?
MRUS

Insider Monkey

23 days ago

Is Merus (NASDAQ:MRUS) the Best High Short Interest Stock to Buy Now?

Strength Seen in BioMarin (BMRN): Can Its 6.3% Jump Turn into More Strength?
MRUS

Zacks

a month ago

Strength Seen in BioMarin (BMRN): Can Its 6.3% Jump Turn into More Strength?

Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
MRUS

GlobeNewswire

a month ago

Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

Analyst Forecasts Just Became More Bearish On Merus N.V. (NASDAQ:MRUS)
MRUS

Simply Wall St.

2 months ago

Analyst Forecasts Just Became More Bearish On Merus N.V. (NASDAQ:MRUS)

Merus N.V. (MRUS) Reports Q4 Loss, Lags Revenue Estimates
MRUS

Zacks

2 months ago

Merus N.V. (MRUS) Reports Q4 Loss, Lags Revenue Estimates

Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update
MRUS

GlobeNewswire

2 months ago

Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update

Merus to Present at Upcoming Investor Conferences
MRUS

GlobeNewswire

3 months ago

Merus to Present at Upcoming Investor Conferences

Will Iovance Biotherapeutics (IOVA) Report Negative Earnings Next Week? What You Should Know
MRUS

Zacks

3 months ago

Will Iovance Biotherapeutics (IOVA) Report Negative Earnings Next Week? What You Should Know

MRUS

MT Newswires

3 months ago

Merus Says US FDA Grants Breakthrough Therapy Designation to Petosemtamab

Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
MRUS

GlobeNewswire

3 months ago

Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma

Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit
MRUS

GlobeNewswire

3 months ago

Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit

MRUS

MT Newswires

3 months ago

Piper Sandler Initiates Merus at Overweight With $84 Price Target

MRUS

MT Newswires

3 months ago

Wells Fargo Initiates Merus at Overweight With $91 Price Target

New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
MRUS

GlobeNewswire

3 months ago

New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus N.V. (MRUS): The Biotech Stock with Biggest Upside Potential
MRUS

Insider Monkey

4 months ago

Merus N.V. (MRUS): The Biotech Stock with Biggest Upside Potential

Companies Like Merus (NASDAQ:MRUS) Are In A Position To Invest In Growth
MRUS

Simply Wall St.

4 months ago

Companies Like Merus (NASDAQ:MRUS) Are In A Position To Invest In Growth

MRUS

MT Newswires

4 months ago

Merus, Biohaven Partner to Develop Bispecific Therapies for Cancers

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
MRUS

GlobeNewswire

4 months ago

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

Jim Cramer Says Merus (MRUS) Still ‘Very Speculative’
MRUS

Insider Monkey

4 months ago

Jim Cramer Says Merus (MRUS) Still ‘Very Speculative’

MRUS

MT Newswires

5 months ago

Merus Reports First Person Dosed in Mid-Stage Petosemtamab Trial

Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC
MRUS

GlobeNewswire

5 months ago

Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC

Merus (MRUS): FDA Approval and Speculative Future in Cancer Therapy
MRUS

Insider Monkey

5 months ago

Merus (MRUS): FDA Approval and Speculative Future in Cancer Therapy

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
MRUS

GlobeNewswire

5 months ago

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus Scores Its First FDA Approval For Lung Cancer Drug
MRUS

Benzinga

5 months ago

Merus Scores Its First FDA Approval For Lung Cancer Drug

Merus’ Bizengri granted FDA accelerated approval to treat NRG1+ cancers
MRUS

Clinical Trials Arena

5 months ago

Merus’ Bizengri granted FDA accelerated approval to treat NRG1+ cancers

MRUS

MT Newswires

5 months ago

Merus Gets US FDA Approval for Bizengri in Advanced Pancreatic, Lung Cancers

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study
MRUS

GlobeNewswire

5 months ago

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus price target lowered to $109 from $111 at Guggenheim
MRUS

TipRanks

5 months ago

Merus price target lowered to $109 from $111 at Guggenheim

Merus Licenses US Commercialization Rights For Cancer Potential Zenocutuzumab, Analyst Highlight Merus' Pipeline
MRUS

Benzinga

5 months ago

Merus Licenses US Commercialization Rights For Cancer Potential Zenocutuzumab, Analyst Highlight Merus' Pipeline

MRUS

MT Newswires

5 months ago

Merus Licenses Potential Lung, Pancreatic Cancer Treatment to Partner Therapeutics

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer
MRUS

GlobeNewswire

5 months ago

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024
MRUS

GlobeNewswire

5 months ago

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus NV (MRUS): Among the Most Promising Cancer Stocks According to Hedge Funds
MRUS

Insider Monkey

6 months ago

Merus NV (MRUS): Among the Most Promising Cancer Stocks According to Hedge Funds

PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...
MRUS

GuruFocus.com

6 months ago

PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...

Is Merus N.V. (MRUS) Top Performing European Stock Heading into 2025?
MRUS

Insider Monkey

6 months ago

Is Merus N.V. (MRUS) Top Performing European Stock Heading into 2025?

Merus to Present at Upcoming Investor Conferences
MRUS

GlobeNewswire

6 months ago

Merus to Present at Upcoming Investor Conferences

MRUS

MT Newswires

6 months ago

Merus Gets FDA Extension on Prescription Drug User Fee Act Goal Date for Zenocutuzumab to Feb. 4

Merus Receives FDA extension of PDUFA for zenocutuzumab
MRUS

GlobeNewswire

6 months ago

Merus Receives FDA extension of PDUFA for zenocutuzumab

Merus Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
MRUS

Simply Wall St.

6 months ago

Merus Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

MRUS

MT Newswires

6 months ago

Merus's Shares Dip After Reporting Wider-Than-Expected Q3 Net Loss

Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates
MRUS

Zacks

6 months ago

Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates

Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update
MRUS

GlobeNewswire

6 months ago

Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update

MRUS

MT Newswires

7 months ago

UBS Initiates Merus With Buy Rating, $72 Price Target

Investing in Merus (NASDAQ:MRUS) five years ago would have delivered you a 227% gain
MRUS

Simply Wall St.

7 months ago

Investing in Merus (NASDAQ:MRUS) five years ago would have delivered you a 227% gain

MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains?
MRUS

Zacks

7 months ago

MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains?

Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC
MRUS

GlobeNewswire

7 months ago

Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC

TimesSquare Capital Management U.S. Small Cap Growth Strategy Established a Position in Merus N.V. (MRUS)
MRUS

Insider Monkey

8 months ago

TimesSquare Capital Management U.S. Small Cap Growth Strategy Established a Position in Merus N.V. (MRUS)

Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024
MRUS

GlobeNewswire

8 months ago

Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024

Merus NV (MRUS): Short Seller Sentiment is Bearish on This Cancer Stock
MRUS

Insider Monkey

8 months ago

Merus NV (MRUS): Short Seller Sentiment is Bearish on This Cancer Stock

Merus NV (MRUS): Top ADR Stock According to Hedge Funds
MRUS

Insider Monkey

8 months ago

Merus NV (MRUS): Top ADR Stock According to Hedge Funds

MRUS

MT Newswires

9 months ago

Merus Insider Sold Shares Worth $270,000, According to a Recent SEC Filing

We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate
MRUS

Simply Wall St.

9 months ago

We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate

Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference
MRUS

GlobeNewswire

9 months ago

Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference

Merus N.V. (MRUS) Reports Q2 Loss, Lags Revenue Estimates
MRUS

Zacks

9 months ago

Merus N.V. (MRUS) Reports Q2 Loss, Lags Revenue Estimates

Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
MRUS

GlobeNewswire

9 months ago

Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update

Agenus (AGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
MRUS

Zacks

9 months ago

Agenus (AGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
MRUS

Zacks

9 months ago

Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC
MRUS

GlobeNewswire

10 months ago

Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC

Institutional investors control 69% of Merus N.V. (NASDAQ:MRUS) and were rewarded last week after stock increased 5.5%
MRUS

Simply Wall St.

10 months ago

Institutional investors control 69% of Merus N.V. (NASDAQ:MRUS) and were rewarded last week after stock increased 5.5%

MRUS

MT Newswires

10 months ago

Merus Begins Phase 2 Trial of Colorectal Cancer Drug Candidate

Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC
MRUS

GlobeNewswire

10 months ago

Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC

MRUS

MT Newswires

10 months ago

Sector Update: Health Care Stocks Retreat Late Afternoon

MRUS

MT Newswires

10 months ago

Merus Names New Chief Medical Officer

Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer
MRUS

GlobeNewswire

10 months ago

Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer

MRUS

MT Newswires

a year ago

Stifel Nicolaus Adjusts Merus N.V Price Target to $99 From $90, Maintains Buy Rating

MRUS

MT Newswires

a year ago

Merus Insider Sold Shares Worth $475,456, According to a Recent SEC Filing

MRUS

MT Newswires

a year ago

BMO Capital Raises Price Target on Merus to $91 From $84, Maintains Outperform Rating

MRUS

MT Newswires

a year ago

Canaccord Genuity Adjusts Price Target on Merus to $67 From $54, Maintains Buy Rating

MRUS

MT Newswires

a year ago

Merus Says Target Tumors in Lung Cancer Patients Decrease in Size After MCLA-129 Treatment

Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting
MRUS

GlobeNewswire

a year ago

Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting

MRUS

MT Newswires

a year ago

Truist Securities Raises Price Target on Merus to $88 From $69, Maintains Buy Rating

Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
MRUS

GlobeNewswire

a year ago

Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting

MRUS

MT Newswires

a year ago

Merus Prices $400.2 Million Public Share Offering

Merus Announces Pricing of Upsized Public Offering of Common Shares
MRUS

GlobeNewswire

a year ago

Merus Announces Pricing of Upsized Public Offering of Common Shares

These Analysts Think Merus N.V.'s (NASDAQ:MRUS) Sales Are Under Threat
MRUS

Simply Wall St.

a year ago

These Analysts Think Merus N.V.'s (NASDAQ:MRUS) Sales Are Under Threat

MRUS

MT Newswires

a year ago

BofA Securities Adjusts Merus Price Target to $80 From $61, Maintains Buy Rating

Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
MRUS

GlobeNewswire

a year ago

Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

MRUS

MT Newswires

a year ago

HC Wainwright Adjusts Price Target on Merus to $85 From $65, Maintains Buy Rating

MRUS

MT Newswires

a year ago

Merus Launches $300 Million Stock Offering

Merus N.V. Announces Proposed Public Offering of Common Shares
MRUS

GlobeNewswire

a year ago

Merus N.V. Announces Proposed Public Offering of Common Shares

MRUS

MT Newswires

a year ago

Guggenheim Adjusts Merus Price Target to $93 From $57, Maintains Buy Rating

MRUS

MT Newswires

a year ago

BMO Capital Adjusts Merus Price Target to $84 From $58, Maintains Outperform Rating

MRUS

MT Newswires

a year ago

Stifel Adjusts Price Target on Merus to $90 From $65, Maintains Buy Rating

Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC
MRUS

GlobeNewswire

a year ago

Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC

Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data
MRUS

Zacks

a year ago

Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data

Why Top 4% Biotech Stock, Merus, Just Catapulted To A Record High
MRUS

Investor's Business Daily

a year ago

Why Top 4% Biotech Stock, Merus, Just Catapulted To A Record High

Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?
MRUS

Benzinga

a year ago

Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?

MRUS

MT Newswires

a year ago

Top Midday Gainers

Merus Clears Wall Street's Bar With Cancer Data
MRUS

Barrons.com

a year ago

Merus Clears Wall Street's Bar With Cancer Data

MRUS

MT Newswires

a year ago

Merus Rallies Ahead of Upcoming Presentations for Prospective Cancer Treatments, Price Target Boost at BoA Securities

Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.
MRUS

Barrons.com

a year ago

Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.

MRUS

MT Newswires

a year ago

BofA Adjusts Price Target on Merus to $61 From $52, Maintains Buy Rating

Share on Social Networks: